SCHEMBL1375324

SCHEMBL1375324

NC(=O)c1ccc(-c2ccc(C(=O)O)c(OCc3cccc4ccccc34)c2)cc1

nearest known ligand 0.69

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ FDPS P14324 1/20 0.69
▸ PARP10 Q53GL7 4/20 0.65
▸ MEN1 O00255 4/20 0.58
▸ KMT2A Q03164 4/20 0.58
▸ PARP15 Q460N3 2/20 0.55
▸ MCL1 Q07820 2/20 0.51
▸ FFAR1 O14842 1/20 0.44
▸ AKR1B1 P15121 1/20 0.44
▸ MRGPRX4 Q96LA9 1/20 0.43
▸ PDE4A P27815 1/20 0.43
▸ PDE4B Q07343 1/20 0.43
▸ PDE4C Q08493 1/20 0.43
▸ PDE4D Q08499 1/20 0.43
▸ MAOB P27338 1/20 0.43
▸ PARP14 Q460N5 1/20 0.43
▸ ADAMTS4 O75173 1/20 0.42
▸ MMP13 P45452 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1378315 0.91 FDPS (0.78) FDPSPARP10MEN1KMT2APARP15
SCHEMBL12149699 0.89 FDPS (0.74) FDPSPARP10MEN1KMT2APARP15
SCHEMBL1375089 0.88 PARP10 (0.61) FDPSPARP10MEN1KMT2APARP15
SCHEMBL12149685 0.86 FDPS (0.72) FDPSPARP10MEN1KMT2APARP15
SCHEMBL12149679 0.86 FDPS (0.72) FDPSPARP10MEN1KMT2APARP15
SCHEMBL12149675 0.85 FDPS (0.70) FDPSPARP10MEN1KMT2APARP15
SCHEMBL12149587 0.85 FDPS (0.70) FDPSPARP10MEN1KMT2APARP15
SCHEMBL12149684 0.85 FDPS (0.70) FDPSPARP10MEN1KMT2APARP15
SCHEMBL1375062 0.83 FDPS (0.65) FDPSPARP10MEN1KMT2APARP15
SCHEMBL12149693 0.83 FDPS (0.70) FDPSPARP10MEN1KMT2APARP15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110288057-A1 SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS NOVARTIS AG (CH) 2011-11-24 — — US claimed
CN-102186803-A Salicylic acid derivatives being farnesyl pyrophosphate synthase activity inhibitors NOVARTIS AG 2011-09-14 — — CN claimed
EP-2342173-A1 SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS Novartis AG (CH) 2011-07-13 — — EP claimed
WO-2010043584-A1 SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS NOVARTIS AG (CH) 2010-04-22 — — WO claimed
US-20110288057-A1 SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS NOVARTIS AG (CH) 2011-11-24 — — US disclosed
EP-2342173-A1 SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS Novartis AG (CH) 2011-07-13 — — EP disclosed
WO-2010043584-A1 SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS NOVARTIS AG (CH) 2010-04-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110288057-A1 SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS FDPS, GGPS1, COASY FDPS 1/4885PARP10 1018/4885MEN1 2332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback